Old diagnosis, new drugs — but not for everyone. A Danish study found that heart failure patients diagnosed before key guideline updates were 43% less likely to receive ARN inhibitors and 28% less likely to receive SGLT2 inhibitors compared to those diagnosed after the updates. Researchers say targeted interventions like clinical decision-support tools and proactive patient recalls are needed to close this treatment gap.
When clinical guidelines get updated, not all patients benefit equally. A large Danish cohort study found that heart failure (HF) patients diagnosed before major guideline updates were significantly less likely to be prescribed newer, evidence-based therapies compared to those diagnosed after the updates — even when those older patients were still eligible for treatment.
The study examined two drug classes: ARN inhibitors (recommended in 2016) and SGLT2 inhibitors (recommended in 2021). Researchers analyzed data from over 60,000 patients for ARN inhibitors and over 23,000 for SGLT2 inhibitors, adjusting for comorbidities, demographics, and socioeconomic factors.
By the Numbers:
Why it matters: This "implementation gap" means thousands of existing HF patients may be missing out on therapies proven to improve outcomes. Researchers call for proactive solutions — like clinical decision-support tools and systematic patient list reviews — to ensure guideline updates translate into real-world care for all eligible patients, not just newly diagnosed ones.
